NG
PTGX icon

Norden Group’s Protagonist Therapeutics PTGX Stock Holding History

Norden Group’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$296K Buy
+2,810
New +$249K 0.03% 470

Other funds holding PTGX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return

Norden Group's PTGX Position: Q1 2026 in Review

Norden Group opened a new position in Protagonist Therapeutics (PTGX) in Q1 2026: 2,810 shares worth $296K. The stake represents 0.03% of the portfolio and ranks #470 among its holdings.

317 funds tracked by Wall St. Rank hold PTGX as of Q1 2026.

  • Norden Group held 2,810 shares of Protagonist Therapeutics worth $296K as of Q1 2026.
  • Protagonist Therapeutics was a new Norden Group position in Q1 2026.
  • Protagonist Therapeutics made up 0.03% of Norden Group's portfolio in Q1 2026, its #470 holding.
  • 317 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q1 2026.

Based on Norden Group's 13F filing for Q1 2026, filed 15 Apr 2026.